RRM2, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-RRM2, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | RRM2, Human |
| Clone | REAL1010 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | RRM2 Antibody, anti-human, PE, REAdye_lease™. Clone REAL1010 is an antibody fragment derived from the full RRM2 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1010 recognizes RRM2, also known as Ribonucleotide reductase M2, which is one of the two different subunits of ribonucleotide reductase. RRM2 is a rate-limiting enzyme involved in DNA repair and synthesis, that catalyzes the biosynthesis of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. RRM2 plays an active role in tumor progression and metastasis. It is frequently overexpressed in cancer, including glioblastoma, oral squamous cell carcinoma (OSCC) and gastric cancer and is identified as a therapeutic target. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | |
| Immunogen | n/a |
| Other Names | Ribonucleotide reductase M2, RR2, RR2M |
| Gene, Accession # | n/a |
| Catalog # | 130-127-838 |
| Price | $510 |
| Order / More Info | RRM2, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Zhang, K. et al. (2009) Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer. 8: 11. | Li, C. et al. (2018) J Cell Physiol 2018 Oct;233(10):6759-6767. RRM2 promotes the progression of human glioblastoma. J. Cell. Physiol. 233 (10): 6759-6767. | Zhan, Y. et al. (2020) Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother . 133: 110996. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies